Who owns Kalaris Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of KLRS from SEC Form 13F filings across 56 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 56 institutions disclosed 18.0M shares of Kalaris Therapeutics, Inc. worth $73.4M — about 75.8% of shares outstanding; the largest disclosed holder is SAMSARA BIOCAPITAL, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
56
13F holders
$73.4M
value, 2026 filers
75.8%
of shares outstanding (18.0M sh)
9
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of KLRS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | SAMSARA BIOCAPITAL, LLC | 12.9M | $52.4M | 4.3% | 54.1% | -0.5% |
| 2 | RTW INVESTMENTS, LP | 1.3M | $5.3M | 0.0% | 5.5% | 0.0% |
| 3 | Alyeska Investment Group, L.P. | 572,687 | $2.3M | 0.0% | 2.4% | 0.0% |
| 4 | Siren, L.L.C. | 435,798 | $1.8M | 0.0% | 1.8% | 0.0% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 398,712 | $1.6M | 0.0% | 1.7% | +56.1% |
| 6 | Ikarian Capital, LLC | 360,000 | $1.5M | 0.2% | 1.5% | 0.0% |
| 7 | UBS Group AG | 262,131 | $1.1M | 0.0% | 1.1% | +4138.9% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 149,351 | $607,859 | 0.0% | 0.6% | +125.8% |
| 9 | MARSHALL WACE, LLP | 139,201 | $566,549 | 0.0% | 0.6% | +105.1% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 114,037 | $464,287 | 0.0% | 0.5% | +30.3% |
| 11 | ADAR1 Capital Management, LLC | 100,000 | $407,000 | 0.0% | 0.4% | 0.0% |
| 12 | Woodline Partners LP | 100,000 | $407,000 | 0.0% | 0.4% | 0.0% |
| 13 | WHI TRUST Co LLC | 97,493 | $396,797 | 0.3% | 0.4% | 0.0% |
| 14 | RAYMOND JAMES FINANCIAL INC | 97,164 | $395,457 | 0.0% | 0.4% | -18.3% |
| 15 | CITADEL ADVISORS LLCNEW | 95,772 | $389,792 | 0.0% | 0.4% | new |
| 16 | BOOTHBAY FUND MANAGEMENT, LLC | 92,261 | $375,502 | 0.0% | 0.4% | 0.0% |
| 17 | Verdad Advisers, LPNEW | 80,297 | $326,809 | 0.3% | 0.3% | new |
| 18 | MORGAN STANLEY | 72,326 | $294,367 | 0.0% | 0.3% | +88.6% |
| 19 | VANGUARD FIDUCIARY TRUST CO | 66,179 | $269,349 | 0.0% | 0.3% | +80.2% |
| 20 | BlackRock, Inc. | 54,442 | $221,580 | 0.0% | 0.2% | +51.0% |
| 21 | Belpointe Asset Management LLC | 40,000 | $162,800 | 0.0% | 0.2% | 0.0% |
| 22 | Fortis Capital Advisors, LLC | 40,000 | $162,800 | 0.0% | 0.2% | 0.0% |
| 23 | Pale Fire Capital SENEW | 39,626 | $161,278 | 0.0% | 0.2% | new |
| 24 | Squarepoint Ops LLC | 38,775 | $157,814 | 0.0% | 0.2% | -2.5% |
| 25 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 32,500 | $132,275 | 0.0% | 0.1% | +44.4% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.